Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity

Abstract
Purpose: BMS-275183 is an orally administered C-4 methyl carbonate analogue of paclitaxel. We did a dose-escalating phase I study to investigate its safety, tolerability, pharmacokinetics, and possible antitumor activity.

This publication has 26 references indexed in Scilit: